FDA Approves the First Insulin Pump and Glucose Monitoring System for Children

| Printer friendly version

West Chester, Pennsylvania-based Animas Corporation recently announced FDA approval for the use of the Animas® Vibe® Insulin Pump and Continuous Glucose Monitoring (CGM) System for children and adolescents, ages two to seventeen. A Johnson & Johnson Diabetes company, Animas brings the industry one step closer to bringing a viable artificial pancreas to the market that is approved for pediatric patients.

Although previously approved for adult patients eighteen and older, children have greater insulin sensitivities than adults, and have a lower compliance with regular injections throughout the day. In addition, parents and caregivers are constantly required to monitor glucose levels and worry throughout the day about injections.

According to Animas, the Vibe System is the only integrated system available for pediatric patients as young as age two. The system allows the patient, and parents and caregivers, to deliver insulin and to monitor glucose trends in children. Diabetes patients, and especially children, cannot always feel the symptoms of when glucose levels are too low or too high, but the Animas Vibe System provides customizable alerts and alarms to provide the information to the patient.

According to John Wilson, Vice President of Insulin Delivery, Animas:

We’re thrilled that the FDA approval of this new indication for the Animas® Vibe® System for the first time now allows children as young as age two access to a CGM-enabled pump.

In its press release, Animas emphasized the value of insulin pump therapy in assisting patients to make more informed decisions about their insulin needs. According to Animas, the therapy has been demonstrated as an effective and significant improvement in blood glucose control compared to multiple daily injections of insulin.

Robert Hilton
Dr. Robert J. Hilton focuses primarily on patent prosecution in the chemistry and life sciences fields. Robert assists a wide range of clients, including small and large companies locally and internationally. He currently represents clients with technology in the fields of stem cells, CAR T cells, prostate cancer therapeutics and other oncology pharmaceuticals, vaccines, medical devices, dietary supplements, diagnostic devices and assays, cosmetics, and therapeutic antibodies. Robert earned his Ph.D. in biochemistry from BYU. His research involved the studies of metals in biological systems, including metal dysregulation in diseases such as chronic kidney disease.
Click here to read full bio
View all posts published by Robert Hilton »

One Response

  1. Jonam
    March 18, 2016 at 11:07 pm |

    The approval of the first insulin pump and the glucose monitoring system for the children by the FDA is a great news, thanks for such a great information that can change many children’s life similar to this important update, more updates can be found here More new updates on FDA

    Reply

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.